H.C. Wainwright lowered the firm’s price target on UroGen Pharma (URGN) to $40 from $50 and keeps a Buy rating on the shares. The firm revised long-term sales projections post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
- Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
- UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
- UroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
- UroGen Pharma announces publication of Phase 3b ZUSDURI study results